Načítá se...
Novel antigens of CAR T cell therapy: New roads; old destination
Chimeric antigen receptor T cell (CAR-T) therapy has so far proved itself as a reliable therapeutic option for the treatment of relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), and mantle cell lymphoma (MCL). However...
Uloženo v:
| Vydáno v: | Transl Oncol |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Neoplasia Press
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8065293/ https://ncbi.nlm.nih.gov/pubmed/33862524 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tranon.2021.101079 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|